Crohn’s Disease and Cancer

  • Fabio Calabrò
  • Cora N. Sternberg
Part of the Updates in Surgery book series (UPDATESSURG)


Inflammatory bowel disease (IBD) is a group of inflammatory conditions of both the large and small intestine. The major types of IBD are Crohn’s disease (CD) and ulcerative colitis (UC). CD is also known as granulomatous colitis, regional enteritis, and i leitis. It is an inflammatory disease that may affect any part of the gastrointestinal tract from the mouth to the anus, causing a wide variety of symptoms. Because the symptoms of CD are similar to other intestinal disorders, such as irritable bowel syndrome and UC, it can be difficult to diagnose. In CD, all layers of the intestine may be involved, and normal healthy bowel can be found between sections of diseased bowel.


Colorectal Cancer Inflammatory Bowel Disease Ulcerative Colitis Adenomatous Polyposis Coli Carcinoid Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schreiber S, Rosenstiel P, Albrecht M et al (2005) Genetics of Crohn disease, an archetypal inflammatory barrier disease. Nat Rev Genet 6(5):376–388CrossRefPubMedGoogle Scholar
  2. 2.
    Sartor RB (2006) Mechanisms of disease: Pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 3(7):390–407CrossRefPubMedGoogle Scholar
  3. 3.
    Eaden JA, Abrams KR, Mayberry JF (2001) The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut 48(4):526–535CrossRefPubMedGoogle Scholar
  4. 4.
    van Staa TP, Card T, Logan RF et al (2005) 5-Aminosalicylate us and colorectal risk in inflammatory bowel disease: A large epidemiological study. Gut 54(11):1573–1578CrossRefPubMedGoogle Scholar
  5. 5.
    Baumgart DC, Sandborn WJ (2007) Inflammatory bowel disease: Clinical aspects and established and evolving therapies. Lancet 369:1641–1657CrossRefPubMedGoogle Scholar
  6. 6.
    Blomqvist P, Feltelius N, Löfberg R et al (2001) A 10-year survey of inflammatory bowel diseases-drug therapy, costs and adverse reactions. Aliment Pharmacol Ther 15:475–481CrossRefPubMedGoogle Scholar
  7. 7.
    Gyde SN, Prior P, Macartney JC et al (1980) Malignancy in Crohn’s disease. Gut 21:1024–1029CrossRefPubMedGoogle Scholar
  8. 8.
    Ekbom A, Helmick C, Zack M et al (1990) Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet 336:357–359CrossRefPubMedGoogle Scholar
  9. 9.
    Canavan D, Abrams KR, Mayberry J (2006) Meta-Analysis colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther 23:1097–1104CrossRefPubMedGoogle Scholar
  10. 10.
    Jess T, Gamborg M, Matzen P et al (2005) Increased risk of intestinal cancer in Crohn’s disease: A meta-analysis of population-based cohort studies. Am J Gastroenterol 100:2724–2729CrossRefPubMedGoogle Scholar
  11. 11.
    Gillen CD, Walmsley RS, Prior P et al (1994) Ulcerative colitis and Crohn’s disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 25:1590–1592CrossRefGoogle Scholar
  12. 12.
    Bernstein CN, Blanchard JF, Kliewer E et al (2001) Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91:854–862CrossRefPubMedGoogle Scholar
  13. 13.
    Jess T, Loftus EV Jr, Velayos FS et al (2006) Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Gastroenterology 130:1039–1046CrossRefPubMedGoogle Scholar
  14. 14.
    Koga H, Aoyagi K, Hizawa K et al (1999) Rapidly and infiltratively growing Crohn’s carcinoma of the small bowel: serial radiologic findings and a review of the literature. Clin Imaging 23:298–301CrossRefPubMedGoogle Scholar
  15. 15.
    Solem CA, Harmsen WS, Zinsmeister AR et al (2004) Small intestinal adenocarcinoma in Crohn’s disease: a case-control study. Inflamm Bowel Dis 10:32–35CrossRefPubMedGoogle Scholar
  16. 16.
    Jess T, Winther KV, Munkholm P et al (2004) Intestinal and extra-intestinal cancer in Crohn’s disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther 19:287–293CrossRefPubMedGoogle Scholar
  17. 17.
    Barwood N, Platell C (1999) Case report: adenocarcinoma arising in a Crohn’s stricture of the jejunum. J Gastroenterol Hepatol 14:1132–1134CrossRefPubMedGoogle Scholar
  18. 18.
    Marchetti F, Faxio VW, Ozuner G (1996) A denocarcinoma arising from a structureplasty site in Crohn’s disease. Report of a case. Dis Colon Rectum 39:1315–1321CrossRefPubMedGoogle Scholar
  19. 19.
    Partridge SK, Hodin RA (2004) Small bowel adenocarcinoma at a strictureplasty site in a patient with Crohn’s disease: report of a case. Dis Colon Rectum 47:778–781CrossRefPubMedGoogle Scholar
  20. 20.
    Sigel JE, Petras RE, Lashner BA et al (1999) Intestinal adenocarcinoma in Crohn’s disease: a report of 30 cases with a focus on coexisting dysplasia. Am J Surg Pathol 23:651–655CrossRefPubMedGoogle Scholar
  21. 21.
    Petras RE, Mir-Madjlessi SH, Farmer RG (1987) Crohn’s disease and intestinal carcinoma. A report of 11 cases with emphasis on associated epithelial dysplasia. Gastroenterology 93:1307–1314PubMedGoogle Scholar
  22. 22.
    Christodoulou D, Skopelitou AS, Katsanos KH et al (2002) Small bowel adenocarcinoma presenting as a first manifestation of Crohn’s disease: report of a case, and a literature review. Eur J Gastroenterol Hepatol 14:805–810CrossRefPubMedGoogle Scholar
  23. 23.
    West NE, Wise PE, Herline AJ et al (2007) Carcinoid tumors are 15 times more common in patients with Crohn’s disease. Inflamm Bowel Dis 13:1129–1134CrossRefPubMedGoogle Scholar
  24. 24.
    Gordon, JN, MacDonald TT (2005) Osteopontin: a new addition to the constellation of cytokines which drive T helper cell type 1 responses in Crohn’s disease. Gut 54:1213–1215CrossRefPubMedGoogle Scholar
  25. 25.
    Askling J, Dickman PW, Karlén P et al (2001) Family history as risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 120:1356–1362CrossRefPubMedGoogle Scholar
  26. 26.
    Jayaram H, Satsangi J, Chapman RW (2001) Increased colorectal neoplasia in chronic ulcerative colitis complicated by primary sclerosing cholangitis: Fact or fiction? Gut 48:430–434CrossRefPubMedGoogle Scholar
  27. 27.
    Xie J, Itzkowitz SH (2008) Cancer in inflammatory bowel disease. World J Gastroenterol 14:378–389CrossRefPubMedGoogle Scholar
  28. 28.
    Stahl TJ, Schoetz DJ Jr, Roberts PL et al (1992) Crohn’s disease and carcinoma: increasing justification for surveillance? Dis Colon Rectum 35:850–856CrossRefPubMedGoogle Scholar
  29. 29.
    Hamilton SR (1985) Colorectal carcinoma in patients with Crohn’s disease. Gastroenterology 89:398–407PubMedGoogle Scholar
  30. 30.
    Svrcek M, Cosnes J, Beaugerie L et al (2007) Colorectal neoplasia in Crohn’s colitis: a retrospective comparative study with ulcerative colitis. Histopathology 50:574–583CrossRefPubMedGoogle Scholar
  31. 31.
    Itzkowitz SH, Yio X (2004) Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: The role of inflammation. Am J Physiol Gastrointest Liver Physiol 287:G7–17CrossRefPubMedGoogle Scholar
  32. 32.
    Sato F, Shibata D, Harpaz N et al (2002) Aberrant methylation of the HPP1 gene in ulcerative colitis-associated colorectal carcinoma. Cancer Res 62:6820–6822PubMedGoogle Scholar
  33. 33.
    Redston MS, Papadopoulos N, Caldas C et al (1995) Common occurrence of APC and K-ras gene mutations in the spectrum of colitis-associated neoplasias. Gastroenterology 108:383–392CrossRefPubMedGoogle Scholar
  34. 34.
    Burmer GC, Rabinovitch PS, Haggitt RC et al (1992) Neoplastic progression in ulcerative colitis: Histology, DNA content, and loss of a p53 allele. Gastroenterology 103:1602–1610PubMedGoogle Scholar
  35. 35.
    Riddell RH, Goldman H, Ransohoff DF et al (1983) Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 14:931–968CrossRefPubMedGoogle Scholar
  36. 36.
    Rubin DT, Rothe JA, Hetzel JT et al (2007) Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc 65:998–1004CrossRefPubMedGoogle Scholar
  37. 37.
    Odze RD, Goldblum J, Noffsinger A et al (2002) Interobserver variability in the diagnosis of ulcerative colitis-associated dysplasia by telepathology. Mod Pathol 15:379–386CrossRefPubMedGoogle Scholar
  38. 38.
    Bernstein CN, Shanahan F, Weinstein WM (1994) Are we telling the truth about surveillance colonoscopy in ulcerative colitis? Lancet 343:71–74CrossRefPubMedGoogle Scholar
  39. 39.
    Rutter MD, Saunders BP, Wilkinson KH et al (2006) Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 130:1030–1038CrossRefPubMedGoogle Scholar
  40. 40.
    Connell WR, Sheffield JP, Kamm MA et al (1994) Lower gastrointestinal malignancy in Crohn’s disease. Gut 35:347–352CrossRefPubMedGoogle Scholar
  41. 41.
    Itzkowitz SH, Harpaz N (2004) Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 126:1634–1648CrossRefPubMedGoogle Scholar
  42. 42.
    Friedman S, Rubin PH, Bodian C et al (2008) Screening and surveillance colonoscopy in chronic Crohn’s colitis: results of a surveillance program spanning 25 years. Clin Gastroenterol Hepatol 6:993–998CrossRefPubMedGoogle Scholar
  43. 43.
    Itzkowitz SH, Present DH, Crohn’s and Colitis Foundation of America Colon Cancer in IBD Study Group (2005) Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 11:314–321CrossRefPubMedGoogle Scholar
  44. 44.
    Zisman TL, Rubin DT (2008) Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gasroenterol 14:2662–2669CrossRefGoogle Scholar
  45. 45.
    Collins PD, Mpofu C, Watson AJ et al (2006) Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev CD000279Google Scholar
  46. 46.
    Alos R, Hinojosa J (2008) Timing of surgery in Crohn’s disease: a key issue in the management. World J Gastroenterol 14:5532–5539CrossRefPubMedGoogle Scholar
  47. 47.
    Morpurgo E, Petras R, Kimberling J et al (2003) Characterization and clinical behaviour of Crohn’s disease initially presenting predominantly as colitis. Dis Colon Rectum 46:918–924CrossRefPubMedGoogle Scholar
  48. 48.
    Gumaste V, Sachar DB, Greenstein AJ (1992) Benign and malignant colorectal strictures in ulcerative colitis. Gut 33:938–941CrossRefPubMedGoogle Scholar
  49. 49.
    Velayos FS, Terdiman JP, Walsh JM (2005) Effect of 5-aminosalicylate us on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100:1345–1353CrossRefPubMedGoogle Scholar
  50. 50.
    Bernstein CN, Blanchard JF, Metge C et al (2003) Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol 98:2784–2788CrossRefPubMedGoogle Scholar
  51. 51.
    Zimmerman MJ, Jewell DP (1996) Cytokines and mechanisms of action of glucocorticoids and aminoslaicy lates in the treatment of ulcerative colitis and Crohn’s disease. Aliment Pharmacol Ther 10 (Suppl 2):93–98PubMedGoogle Scholar
  52. 52.
    Allgayer H (2003) Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther 18 (Suppl 2):10–14CrossRefPubMedGoogle Scholar
  53. 53.
    Hasko G, Szabo C, Németh ZH et al (2001) Sulphasalazine inhibits macrophage activation: Inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression. Immunology 103:473–478CrossRefPubMedGoogle Scholar
  54. 54.
    Greten FR, Eckmann L, Greten TF et al (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285–296CrossRefPubMedGoogle Scholar
  55. 55.
    Rousseaux C, Lefebvre B, Dubuguoy L et al (2005) Intestinal anti-inflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 201:1205–1215CrossRefPubMedGoogle Scholar
  56. 56.
    Hanauer SB, Feagan BG, Lichtenstein GR (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359:1541–1549CrossRefPubMedGoogle Scholar
  57. 57.
    Sands BE, Anderson FH, Bernstein CN et al (2004) Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 350:876–885CrossRefPubMedGoogle Scholar
  58. 58.
    Hanauer SB, Sandborn WJ, Rutgeerts P et al (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 130:323–333, quiz 591CrossRefPubMedGoogle Scholar
  59. 59.
    Sandborn WJ, Feagan BG, Stoinoy S et al (2007) Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 357:228–238CrossRefPubMedGoogle Scholar
  60. 60.
    Bongartz T, Sutton AJ, Sweeting MJ et al (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285CrossRefPubMedGoogle Scholar
  61. 61.
    Peyrin-Biroulet L, Deltenre P, De Suray N et al (2008) Efficacy and safety of tumor necrosis factor antogonists in Crohn’s disease: meta-analysis of placebo-controlled trials: Clin Gastroenterol Hepatol 6:644–653CrossRefPubMedGoogle Scholar
  62. 62.
    Delaunoit T, Limburg PJ, Goldberg RM et al (2006) Colorectal cancer prognosis among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 4:335–342CrossRefPubMedGoogle Scholar
  63. 63.
    Tiersten A, Saltz LB (1996) Influence of inflammatory bowel disease on the ability of patients to tolerate systemic fluorouracil-based chemotherapy. J Clin Oncol 14:2043–2046PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2010

Authors and Affiliations

  • Fabio Calabrò
    • 1
  • Cora N. Sternberg
    • 1
  1. 1.Department of Medical OncologySan Camillo-Forlanini HospitalRomeItaly

Personalised recommendations